Edition:
United States

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

991.00DKK
10:59am EDT
Change (% chg)

kr.5.00 (+0.51%)
Prev Close
kr.986.00
Open
kr.987.00
Day's High
kr.993.00
Day's Low
kr.987.00
Volume
14,954
Avg. Vol
12,300
52-wk High
kr.1,300.00
52-wk Low
kr.839.00

Latest Key Developments (Source: Significant Developments)

ALK-Abello: Torii submits paediatric registration application for house dust mite SLIT-tablet in Japan
Friday, 24 Mar 2017 03:00am EDT 

ALK-Abello A/S :ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan.  Full Article

ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet
Thursday, 2 Mar 2017 01:01am EST 

ALK-Abello A/S : Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe) . Approval of the HDM SLIT-tablet is not expected to have an impact on ALK's 2017 financial outlook .CEO says "approval of the HDM SLIT-tablet marks the beginning of a new era for ALK in the USA as we now take full control of the SLIT-tablet portfolio and integrate it into our existing US business".  Full Article

ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet
Wednesday, 1 Mar 2017 06:38pm EST 

ALK-Abello A/S : Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe) . Approval of the HDM SLIT-tablet is not expected to have an impact on ALK's 2017 financial outlook .CEO says "approval of the HDM SLIT-tablet marks the beginning of a new era for ALK in the USA as we now take full control of the SLIT-tablet portfolio and integrate it into our existing US business".  Full Article

Alk submits registration application for ragweed SLIT-tablet in Europe
Thursday, 16 Feb 2017 02:27am EST 

Alk Abello A/S : Alk submits registration application for ragweed SLIT-tablet in Europe .The European regulatory review process is anticipated to take approximately 12 months so that, subject to approval, first market introductions could take place from late 2018.  Full Article

Alk Abello Q4 EBITDA ex-items slightly down at DKK 121 million
Tuesday, 7 Feb 2017 01:30am EST 

Alk Abello A/S : Q4 total revenue 754 million Danish crowns ($108.49 million) versus 687 million crowns year ago . Q4 EBITDA ex-items 121 million crowns versus 123 million crowns year ago . Revenue in North America showed double-digit growth . Says additional close to 300 million crowns will be allocated to number of growth initiatives . Increases its capital expenditure on production capacity by 150 million-200 million crowns . 2017 total revenue is projected at 2.8 billion-3.0 billion crowns . 2017 reported EBITDA is expected at 300 million crowns due to accelerated investments in growth initiatives . Says additional resource allocations will inevitably slow earnings in 2017 when compared to an exceptional 2016 .Proposes 2016 dividend of 5 crowns per share.  Full Article

Alk Abello Q2 EBIT DKK 119 million, beats expectations
Tuesday, 16 Aug 2016 02:04am EDT 

Alk Abello A/S : Q2 total revenue 773 million Danish crowns ($116.5 million)(Reuters poll 688 million crowns) . Q2 EBIT 119 million crowns (Reuters poll 88.6 million crowns) . Updated guidance to reflect H1 2016 performance and a higher than expected order intake in Europe . Guidance assumes 5-10 pct organic growth in base business in H2 2016 and a minor contribution from partnerships . Free cash flow is now expected at 50-100 million crowns (previously better than in 2015) . Full-year revenue in base business is now expected to grow organically by approximately 20 pct (previously: 15 pct) . Full-year revenue is now projected to exceed 2.9 billion crowns .Full-year EBITDA is now expected to exceed 600 million crowns before special items.  Full Article

Merck plans to end partnership agreement with Alk Abello
Wednesday, 27 Jul 2016 01:25am EDT 

Alk Abello A/S : Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement . Said all rights to GRASTEK, RAGWITEK and investigational house dust mite SLIT-tablets for USA, Canada and Mexico to revert to ALK at no fee following six- month transition period . Ongoing registration processes for investigational HDM SLIT-tablet will continue . North America remains major business opportunity and ALK will now undertake full strategic analysis before deciding on revised strategy . Transaction has no impact on ALK's full-year outlook for 2016 .Acting CEO and Chairman Steen Riisgaard said: "The timing of this move is unexpected".  Full Article

Alk Abello: Member of Management Board sells shares worth DKK 2.7 million
Friday, 20 May 2016 09:48am EDT 

Alk Abello A/S :Flemming Pedersen, Member of Board of Management, sold on May 20 a total of 2,191 Alk Abello shares at market value 2.7 million Danish crowns ($407,689).  Full Article

ALK-Abello names Carsten Hellmann new CEO
Wednesday, 18 May 2016 12:59am EDT 

ALK-Abello A/S : Said on Tuesday Board of Directors had appointed Carsten Hellmann as new President and Chief Executive . Hellmann is currently CEO of Merial and Executive Vice President and member of the Executive Committee of Sanofi .Hellmann to take up CEO position no later than Jan. 1, 2017.  Full Article

Alk Abello raises FY 2016 outlook
Wednesday, 4 May 2016 01:45am EDT 

Alk Abello A/S:Says updates FY 2016 guidance to reflect better than expected performance in Q1 and slightly clearer view of unfolding market situation in Europe.Says FY 2016 EBITDA is now expected to increase to around 575 million crowns (previously: about 450 million crowns) before special items, additional sales royalties and milestone payments.Says FY 2016 base business revenue now seen to grow organically by about 15 percent in local currencies to around 2.75 billion crowns (previous expectation: 10 percent growth and revenue of about 2.6 billion crowns).  Full Article

More From Around the Web

BRIEF-ALK-Abello: Torii submits paediatric registration application for house dust mite SLIT-tablet in Japan

* ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan